in which

J is H, R^1, R^1-O-C(O)-, R^1-C(O)-, R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO-$(CHR^2)_p$-;

D is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-$CH((CH_2)_qC(O)OR^1)$-C(O)-, -NR^4-$CH((CH_2)_qC(O)N(R^{2a},R^{2b}))$-C(O)-, -$NR^4$-$CH((CH_2)_qC(O)Het)$-C(O)-, D-1-Tiq, D-3-Tiq, D-Atc, Aic, D-1-Piq or D-3 Piq;

E is -NR^2-CH_2- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl, (1-6C)alkoxy or benzyloxy;

R^1 is selected form (1-12C)alkyl, (2-12C)alkenyl, (2-12C)alkynyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy, oxo, OH, CF_3 or halogen, and from (6-14C)aryl, (7-15C)aralkyl, (8-16C)aralkenyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2, R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)alkenyl, (3-8C)alkynyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen, and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with

(1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is the same as R^2 or is Het-(1-6C)alkyl;

R^4 is H or (1-3C)alkyl;

X and Y are CH or N, with the proviso that they are not both N;

Het is a 4-, 5- or 6-membered heterocycle containing one or more heteroatoms selected from O, N and S;

m is 1 or 2;

p is 1, 2 or 3;

q is 1, 2 or 3;

t is 2, 3 or 4;

or a pharmaceutically acceptable addition salt or solvate thereof.

2. (Amended) The serine protease inhibitor according to claim 1, wherein m is 2; X is CH and Y is CH.

3. (Amended) The serine protease inhibitor according to claim 2, wherein

J is H, R^1 R^1-SO_2-, R^3OOC-$(CHR^2)_p$-, $(R^{2a},R^{2b})N$-CO-$(CHR^2)_p$- or Het-CO(CHR^2)p-;

D is an amino-acid of the formula -NH-CHR^1-C(O)-, -NR^4-CH($(CH_2)_q$C(O)OR^1)-C(O)-, -NR^4-CH($(CH_2)_q$C(O)N(R^{2a},R^{2b}))-C(O)-,

E is -N(3-6C)cycloalkyl-CH_2- or the fragment



, which is unsubstituted or substituted with (1-6C)alkyl or

1-6C)alkoxy;

R^1 is selected from (1-12C)alkyl, (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl, (1-6C)alkoxy or oxo, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisaryl)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy, OH, CF_3 or halogen;

R^2 is H;

R^{2a} and R^{2b} are each independently selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloakyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy and from (6-14C)aryl and (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen;

R^3 is selected from H, (1-8C)alkyl, (3-8C)cycloalkyl and (3-6C)cycloalkyl(1-4C)alkylene, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl;

p is 1;

q is 2;

t is 3 or 4.

4. (Amended) The serine protease inhibitor according to claim 3, wherein

D is an amino-acid of the formula -NH-CHR^1-C(O)- or glutamyl or an (1-6C)alkylester thereof;

R^1 is selected from (3-12C)cycloalkyl and (3-12C)cycloalkyl(1-6C)alkylene, which groups are unsubstituted or substituted with (3-12C)cycloalkyl or (1-6C)alkoxy, and from (6-14C)aryl, (7-15C)aralkyl and (14-20C)(bisary)alkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-12C)cycloalkyl, (1-6C)alkoxy or halogen; and

R^3 is selected from (1-8C)alkyl and (3-8C)cycloalkyl, which are unsubstituted or substituted with (3-6C)cycloalkyl or (1-6C)alkoxy, and from (7-15C)aralkyl, wherein the aryl groups are unsubstituted or substituted with (1-6C)alkyl, (3-6C)cycloalkyl, (1-6C)alkoxy, CF_3 or halogen and from Het-(1-6C)alkyl.

5. (Amended) The serine protease inhibitor according to claim 4, wherein

J is -CH_2COO(1-6C)alkyl, (3-8C)cycloalkyl, -SO_2-10-camphor, -CH_2CONHphenyl or -CH_2CONH(3-8C)cycloalkyl;

D is D-cyclohexylalaninyl, D-phenylalaninyl, D-diphenylalaninyl or glutamyl, or an (1-6C)alkylester thereof; and

E is the fragment



, wherein t is 3 or 4.

6. (Amended) A pharmaceutical composition comprising the serine protease inhibitor of claim 1 and at least one pharmaceutically suitable auxiliary.

NEW CLAIMS:

9. A prodrug of the serine protease inhibitor of claim 1.

10. A method of effecting serine protease inhibition in a mammal, comprising administering an effective amount of a serine protease inhibitor according to claim 1.